Intensity-modulated radiotherapy controls nasopharyngeal carcinoma distant metastasis and improves survival of patients by unknown
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Abstract 
Background: This study evaluated the distant metastatic outcomes in nasopharyngeal carcinoma (NPC) patients 
treated with intensity-modulated radiotherapy (IMRT) plus chemotherapy.
Methods: 530 Non-metastatic NPC patients were retrospectively collected and reviewed after receiving IMRT with or 
without chemotherapy between June 2006 and December 2011. Patients were treated with one fraction of IMRT daily 
for 5 days a week for 69.96–74.09 Gy, while 473 (89.2 %) of patients also received chemotherapy.
Results: Patients were followed up for a median follow-up duration of 49 months (range from 5 to 98 months). After 
treatment, 91 (17.3 %) patients developed distant metastasis. Distant metastasis after treatment was significantly 
associated with advanced 2010 Union for International Cancer Control (UICC)/American Joint Committee on Cancer 
(AJCC) T staging (p = 0.034), N stage (p < 0.001), 2010 UICC/AJCC stage (p < 0.001), and tumor recurrence (p = 0.029). 
However, chemotherapy failed to reduce cancer distant metastasis in early stage patients, the distant metastasis rate 
was 17.5 % in stage III and 24.2 % in stage IVA–B diseases, after IMRT and chemotherapy. The multivariate analysis 
showed that cancer remission duration, treatment modality, and metastatic site (p < 0.001, p = 0.027 and p = 0.022, 
respectively) were all independent predictors for overall survival of NPC patients after IMRT and chemotherapy.
Conclusions: This study provided insight into the effects of IMRT plus chemotherapy in the treatment of NPC. Future 
studies will explore the efficacy of more aggressive systemic therapies for high-risk patients with distant metastasis.
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Background
Nasopharyngeal carcinoma (NPC) is one of the most 
common head and neck malignancies in Asia, in par-
ticular, in Southern China (Jia et al. 2006). Although the 
underlying mechanisms of NPC carcinogenesis have not 
been fully elucidated, current research has shown that a 
combination of multiple risk factors, such as viral infec-
tions, including Epstein-Barr infection, environmental 
risk factors such as consumption of salted fish, and genetic 
susceptibility may induce the development of NPC (Bren-
nan 2006). NPC is more sensitive to radiotherapy and 
chemotherapy, compared with other cancers, which often 
leads to a favorable prognosis (Brennan 2006). In recent 
years, intensity-modulated radiotherapy (IMRT) as a 
novel radiotherapy technology was introduced into clini-
cal practice. The treatment of patients with IMRT led to 
a significant improvement in the local recurrence-free 
survival and overall survival of NPC patients (Peng et al. 
2012). Nevertheless, disease can progress despite treat-
ment, in particular, the distant metastasis. Such complica-
tions therefore dramatically influence treatment efficacy 
and survival (Sun et  al. 2014; Yue et  al. 2014). To attain 
long-term remission of NPC, further studies are required 
in order to better understand the underlying molecular 
mechanisms of disease progression and identify clinical 
factors and treatment options.
Cancer metastasis is a multiple step process in which 
cancer cells migrate from the primary tumor site and 
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enter into the lymphatic system, the bloodstream and/or 
directly invade neighboring tissues, and are then trans-
ported to a distant organ site and establish a secondary 
tumor lesion (Klein 2008). Multiple steps occur during 
metastasis, including angiogenesis, attachment of cancer 
cells to other cells and/or matrix proteins, translocation 
of neoplastic cells across the extracellular matrix barri-
ers and proliferation at the secondary site (Woodhouse 
et  al. 1997). Morphologically, cancer cells will undergo 
epithelial–mesenchymal transition (EMT) to increase 
their mobility and invasion capacity (Yang and Weinberg 
2008) and then undergo metastasis. IMRT and chemo-
therapy induce apoptosis in cancer cells (Marin et  al. 
2015), thereby inhibiting cancer metastasis. However, 
during treatment, cancer cells can develop resistance to 
apoptosis inducing agents; thus, increasing the likelihood 
cancer recurrence may occur.
In this study, we retrospectively analyzed NPC patients 
after IMRT and chemotherapy. The association between 
clinicopathological features and cancer metastasis were 
evaluated. This study aimed to identify high risk factors 
for distant metastasis in NPC after IMRT and chemo-
therapy, furthermore, prospectively guide regarding 
treatment selection and duration for the patients.
Methods
Patients
In this study, we retrospectively collected 530 cases of 
NPC patients who received radical IMRT in Guangxi 
Medical University Cancer Hospital between June 2006 
and December 2011. The inclusion criteria were (1) his-
tologically confirmed NPC, (2) absence of metastasis, (3) 
absence of previous malignancy or other concomitant 
malignant disease, (4) no previous treatment, (5) Kar-
nofsky performance status of 70 or more, (6) completion 
of radical radiotherapy during the study, and (7) absence 
of the development of metastasis during treatment. This 
study was approved by the Ethics Committee of Guangxi 
Medical University Cancer Hospital (Nanning, China).
Radiotherapy and chemotherapy
Before IMRT, patients were underwent a contrast-
enhanced CT to obtain IMRT specification. Briefly, 
patients were immobilized in the supine position with an 
individually manufactured precision mask from head to 
shoulders. After the target delineation finished, data were 
imported to the treatment planning system for treat-
ment design. The prescribed radiation dose was 69.96–
74.09 Gy to the planning target volume (PTV) of GTVnx 
(primary nasopharyngeal gross tumor volume) and 
GTVnd (involving cervical lymph nodes), 60–65.1 Gy to 
the PTV of CTV1 (high-risk regions), and 51.62–57.6 Gy 
to the PTV of CTV2 (low-risk regions and neck nodal 
regions). IMRT was delivered via nine fixed-gantry angles 
with step-and-shoot treatment techniques. All patients 
were treated with one fraction of IMRT daily, 5  days a 
week.
During the course of treatment, 473 (89.2  %) of these 
530 patients also received chemotherapy (57 patients 
were alone treated with IMRT, in which 39 patients had 
early stage disease, another 18 patients with stage III-
IVB disease did not receive chemotherapy due to physi-
cal, economic or personal reasons). Among these 473 
patients, 122 patients were treated with concurrent 
chemotherapy (CCT) alone, 41 patients with neoadjuvant 
chemotherapy (NACT) followed by CCT, 251 patients 
with CCT plus adjuvant chemotherapy (AC), 37 patients 
with NACT + CCT + AC, and the remaining 22 patients 
received NACT alone or AC alone based on drug reac-
tions or patient preference.
The regimens of NACT included two or three cycles of 
cisplatin 80 mg/m2 on day 1 and 5-fluorouracil 750 mg/
m2/day by continuous intravenous infusion on 96 h every 
3  weeks, or docetaxel 75  mg/m2 on day 1 and cisplatin 
80 mg/m2 on day 1 every 3 weeks. CCT consisted of cis-
platin 100 mg/m2 every 3 weeks or 40 mg/m2/week. For 
patients who received AC, cisplatin 80  mg/m2 on day 1 
and 5-fluorouracil 750 mg/m2/day by continuous intrave-
nous infusion on 96 h was repeated every 4 weeks for two 
or three cycles.
Patient follow‑up
After initial treatment, patients were followed up every 
3 months during the first 2 years, every 6 months for the 
next 3 years, and then annually thereafter, unless a recur-
rence or metastasis was detected or the patient died. 
In an initial follow-up visit, patients were given a chest 
X-ray, abdomen ultrasound, magnetic resonance imaging 
(MRI) of the nasopharyngeal and cervical region, and lab-
oratory tests. A CT scan of the chest and abdomen and a 
single-photon emission computed tomography (SPECT) 
scan of all bones were also performed every 6 months. If 
patients were suspected to have metastases, a CT and/
or a SPECT scan of whole body were also performed to 
exclude cancer metastasis. Follow-up data were obtained 
from 98.5  % patients, with the median follow-up time 
being 49  months (range from 5 to 98  months). Distant 
metastases were classified as a single site in the bone, 
lungs, liver, or multiple sites of more than two organs.
Statistical analysis
All statistical analyses were performed using the statis-
tical package SPSS 16.0 (SPSS, Chicago, IL, USA). The 
overall survival time was calculated from the date of radi-
otherapy to the date of death or last follow-up. The χ2 test 
was used to assess association between cancer metastasis 
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and clinical parameters. The Kaplan–Meier curves with 
a log-rank test were performed to calculate overall sur-
vival and distant metastasis rates. The Cox proportional 
hazard model was utilized for univariate and multivari-
ate analyses of overall survival. All statistical tests were 




In this study, we recruited 530 patients, including 394 
males and 136 females (male to female ratio 2.9:1) with 
the median age of 44  years old (range between 16 and 
79  years old). All patients were histologically diagnosed 
with NPC. To enroll into the IMRT protocol, all patients 
were given a complete physical examination, CT or MRI 
scan of the head and neck region, chest radiography/
CT, abdominal ultrasound/CT, and whole body SPECT 
to exclude any distant metastases. Pathology classifica-
tion of NPC was based on the World Health Organiza-
tion (WHO) Grade I (squamous cell carcinoma), Grade 
II (non-keratinizing carcinoma) and Grade III (undiffer-
entiated carcinoma) (Shanmugaratnam and Sobin 1993). 
Patients were staged according to 2010 Union for Inter-
national Cancer Control (UICC) staging system (Edge 
2010). Clinicopathological characteristics of these 530 
patients are summarized in Table 1.
Treatment complications
Acute treatment toxicities involved primarily reactions 
in the oral mucosa, salivary glands and leukocytes. The 
incidence rates of grade 1, 2 and 3 acute mucositis, xeros-
tomia and leukopenia were 24.5, 45.1 and 30.4; 55.5, 39.4 
and 0; 28.7, 60.2 and 4.7  %, respectively; however, no 
grade 4 toxicities observed (Table 2).
Late toxicities included xerostomia, hearing loss, and 
brain injury. Grade 1, 2 and 3 incidences were 68.9, 22.64 
and 0.56 % for xerostomia; 3.02, 1.13 and 0.38 % for hear-
ing loss; 5.1, 0.94 and 0.19 % for brain injury, respectively, 
while 2 patients developed grade 4 brain injury. Late radi-
ation toxicity data are listed in Table 3.
Effect of IMRT and chemotherapy on NPC patients
At the end of this cohort study, 8 patients (1.5  %) were 
lost to follow-up, 101 (19.1 %) died during the study, 91 
(17.2  %) developed distant metastases, and 54 (10.2  %) 
experienced local–regional failure. Statistical data 
showed that patients with metastases had a significantly 
poorer prognosis than those without metastases (Fig. 1a; 
Table  1), i.e., the 1, 3, and 5-year overall survival rates 
of patients with and without metastases were 91, 42, 29 
and 99, 96, 93  %, respectively. Metastasis after IMRT 
was significantly associated with advanced 2010 UICC/
AJCC T staging (p =  0.034), 2010 UICC/AJCC N stag-
ing (p < 0.001), 2010 UICC/AJCC stage (p < 0.001), and 
tumor recurrence (p =  0.029) (Table  1). Among the 91 
patients with metastases, 7 also had local recurrence, 6 
regional recurrence, and 2 local and regional recurrence.
With respect to cancer remission, we calculated dura-
tion from the end of IMRT to confirmation of metasta-
sis. Treatment led to a median remission duration of 
15 months (range from 1 to 44 months). The cumulative 
metastatic rates at 1-, 2-, and 3-years were 38.5 % (35/91), 
70.3 % (64/91) and 95.6 % (87/91), respectively. Metasta-
sis to the lungs was the most frequent, occurring in 43 
patients, including single lung metastasis and combined 
with other organ metastasis, followed by bone metastasis 
Table 1 Association of  clinicopathological features with   
metastasis of NPC
*p<0.05
Clinical characteristics Metastasis Total p value
Yes No
All cases 91 439 530
Age (years) 0.250
 ≥44 52 222 274
 <44 39 217 256
Gender 0.530
 Male 70 324 394
 Female 21 115 136
WHO histology 0.960
 Grade I–II 46 223 269
 Grade III 45 216 261
2010UICC/AJCC T staging 0.034*
 T1 5 59 64
 T2 24 131 155
 T3 28 140 168
 T4 34 109 143
2010UICC/AJCC N staging <0.001*
 N0 3 65 68
 N1 24 170 194
 N2 57 184 241
 N3 7 20 27
2010UICC/AJCC staging <0.001*
 I 0 21 21
 II 9 105 114
 III 42 189 231
 IVA–B 40 124 164
Treatment modality 0.075
 Radiotherapy alone 5 52 57
 Chemoradiotherapy 86 387 473
Recurrence 0.029*
 Yes 15 39 54
 No 76 400 476
Page 4 of 8Chen et al. SpringerPlus  (2016) 5:1459 
in 38 patients and liver metastasis in 34 patients. The 
incidence rate of multi-organ metastasis occurred in 
36.3 % (33/91) patients, while a single site of metastasis 
occurred in 23.1 % (21/91) in the lung, 19.8 % (18/91) in 
the bone, 14.3 % (13/91) in the liver, and 6.5 % (6/91) in 
other organs.
Association of tumor staging with distant metastasis 
after treatment
Our data showed that the 5-year distant metastasis rate 
was 6.7 % in stage I–II, 18.2 % in stage III, and 24.4 % in 
stage IVA–B. Kaplan–Meier curve analysis revealed that 
survival of patients was significantly different between 
distant metastasis and tumor stages (χ2  =  17.401, 
p  <  0.001; Fig.  1b). Distant metastasis rate was signifi-
cantly lower in stage I–II than in stage III (χ2  =  9.490, 
p  =  0.002) or stage IVA–B (χ2  =  17.983, p  <  0.001), 
Table 2 Frequency of acute toxicity during IMRT
Toxicity Grade
0 (%) 1 (%) 2 (%) 3 (%) 4 (%)
Mucositis 0 130 (24.5) 239 (45.1) 161 (30.4) 0
Xerostomia 27 (5.1) 294 (55.5) 209 (39.4) 0 0
Leukopenia 34 (6.4) 152 (28.7) 319 (60.2) 25 (4.7) 0
Table 3 Late toxic effects of radiotherapy
Toxicity Grade
0 (%) 1 (%) 2 (%) 3 (%) 4 (%)
Xerostomia 42 (7.9) 365 (68.9) 120 (22.64) 3 (0.56) 0
Hearing loss 506 (95.47) 16 (3.02) 6 (1.13) 2 (0.38) 0
Brain injury 495 (93.39) 27 (5.1) 5 (0.94) 1 (0.19) 2 (0.38)
Fig. 1 Kaplan-Meier curves of overall survival and distant metastasis rates. a Stratified by tumor metastasis. b Stratified by tumor staging. c Stratified 
by tumor staging with or without CCRT
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whereas there was no significant difference in distant 
metastasis rate between stage III and IVA–B (χ2 = 2.361, 
p = 0.105).
Furthermore, we assessed the effect of concurrent 
chemoradiotherapy (CCRT) on distant metastasis rate 
with different tumor staging after the removal of 18 
stage III-IVB patients from data analysis due to a small 
sample size, and 22 patients who did not receive CCT in 
chemoradiotherapy group were also removed from this 
data analysis. We found that the corresponding 5-year 
distant metastasis rate was 2.6 % in stage I–II RT alone 
and 8 % in stage II CCRT (χ2 = 1.369, p = 0.242; Fig. 1c), 
whereas the 5-year distant metastasis rate was 17.5  % 
in stage III CCRT and 24.2  % in stage IVA–B CCRT. 
The distant metastasis rate was significantly lower in 
stage II CCRT patients than in stage III CCRT patients 
(χ2 = 4.411, p = 0.036; Fig. 1c) or in stage IVA–B CCRT 
patients (χ2 = 9.938, p = 0.002; Fig. 1c). However, there 
was no significant difference in the 5-year distant metas-
tasis observed between stage III and stage IVA–B CCRT 
patients (χ2 = 2.772, p = 0.096; Fig. 1c).
Univariate and multivariate analyses of prognostic factors 
in patients with tumor distant metastasis
We then performed univariate and multivariate analyses 
to determine the factors that were associated with overall 
survival of patients with distant metastasis, using data of 
remission duration, age, gender, T stage, N stage, treat-
ment modality, recurrence, and metastatic site (Table 4). 
Our univariate analysis showed that remission duration 
(HR 0.446; 95  % CI 0.276–0.721; p =  0.001), treatment 
modality (HR 0.303; 95  % CI 0.120–0.766; p  =  0.012), 
and cancer metastatic site (HR 7.341; 95  % CI 1.610–
33.479; p  =  0.010) were significantly associated with 
overall survival in these patients, while the multivariate 
analysis further showed that these three factors were also 
independent predictors for overall survival of patients 
(p < 0.001, p = 0.027 and p = 0.022, respectively). Meta-
static sites were mostly in the lung, bone, liver or multiple 
organs. Survival analysis showed that patients with lung 
metastasis alone had the best overall survival, followed by 
bone metastasis alone, liver metastasis alone and multi-
ple metastases (p = 0.048, Fig. 2).
Discussion
Local recurrence and distant metastasis are the major 
causes of failure in treatment in NPC patients. In recent 
decades, 2- or 3-dimensional radiotherapy, in particular 
IMRT technology, has been used as the primary thera-
peutic approach to treat NPC patients and has shown 
remarkable benefits in local control and relapse-free 
survival of patients (Peng et  al. 2012; Lai et  al. 2011). 
However, distant metastasis is still the leading cause of 
IMRT treatment failure. To date, there were few studies 
that identify and evaluate the precise incidence of NPC 
distant metastasis after IMRT and chemotherapy. In the 
current study, we found that the distant metastasis rate in 
NPC patients was 17.2 %, which was similar to the results 
published in other IMRT studies (Sun et  al. 2014; Yue 
et al. 2014; Lee et al. 2009; Leung et al. 2005). Addition-
ally, we also found that the 1, 3 and 5-year overall sur-
vival rates of patients with and without distant metastasis 
were 91, 42, 29 and 99, 96, 93  %, respectively. Patients 
with distant metastases had a significantly poorer prog-
nosis than patients without metastases. We also analyzed 
clinicopathological features as risk factors that contrib-
uted to NPC distant metastasis. Our results showed that 
advanced T and N stages, advanced clinical stages, and 
tumor recurrence were associated with the development 
of distant metastasis, while remission duration, treatment 
modality, and cancer metastatic site were all independent 
predictors for overall survival of metastatic patients after 
initial treatment. Our current data indicated that iden-
tification of patients with high risk to distant metastasis 
Table 4 Univariate and multivariate analyses of overall survival of patients with metastatic NPC
*p<0.05
Variables Univariate analysis Multivariate analysis
HR 95 % CI p value HR 95 % CI p value
Remission duration 0.446 0.276–0.721 0.001* 0.390 0.233–0.653 <0.001*
Age 1.513 0.925–2.474 0.099
Gender 0.909 0.510–1.619 0.745
2010UICC/AJCC T staging 1.134 0.875–1.469 0.341
2010UICC/AJCC N staging 1.047 0.725–1.513 0.805
2010UICC/AJCC stage 1.085 0.770–1.530 0.640
Treatment modality 0.303 0.120–0.766 0.012* 0.344 0.133–0.885 0.027*
Recurrence 1.210 0.657–2.227 0.541
Metastatic site 7.341 1.610–33.479 0.010* 5.972 1.292–27.609 0.022*
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and choosing effective treatment regimes might lead to 
an increased rate of survival of patients.
In general, tumor T staging is related to local contain-
ment of the tumor, while the N staging is associated with 
distant metastasis (Leung et al. 2005; Li et al. 2014). How-
ever, our current data showed that compared to early T 
stage patients, advanced T stage patients had a higher dis-
tant metastasis rate. In stage T3–4 patients, destruction 
of the base of skull was a common finding. A previous 
study Cheng et  al. (2005) reported that NPC commonly 
invades into the parapharyngeal venous plexus along with 
the marrow of the skull base. Although IMRT improves 
the target dose to the nasopharyngeal region and protects 
tissues near the skull base such as the brain stem and tem-
poral lobe, some targeting doses may not be sufficient to 
eliminate tumor lesions, resulting in an increase in distant 
metastasis. Furthermore, a previous study demonstrated 
that tumor N staging was a predicative factor for distant 
metastasis (Xia et  al. 2013). Our current data were con-
sistent with previous findings. Other studies have also 
revealed that distant metastasis-related free survival was 
proportional to the N staging of the disease (Sun et  al. 
2014; Wang et al. 2014; Wong et al. 2010). Although IMRT 
provides excellent regional treatment of NPC, distant 
metastasis-related free survival was still low in patients 
with advanced N stage disease (Peng et al. 2012). This may 
be due to a higher micrometastatic risk in such patients 
and an increased IMRT dose may be unable to control 
such micrometastatic lesions (Sun et al. 2014).
Furthermore, our current study showed that the local 
recurrence rate was 10.2  % (54/530). Specifically, 15 
of 54 patients presented with distant metastasis dur-
ing follow-up. Two previous studies have shown that 
patients with regional recurrence had an increased risk 
of developing distant metastasis, and thus, regional 
recurrence has been recognized as an independent risk 
predictor for distant metastasis in NPC patients (Peng 
et al. 2013; Kwong et al. 1994). In accordance with these 
studies, our current data also showed a significant asso-
ciation between tumor recurrence and distant metas-
tasis. Additionally, remission duration after treatment 
was an important prognostic factor for overall survival 
of patients with metastatic NPC (Teo et  al. 1996). Our 
current data demonstrated that the median remission 
duration in patients was 15  months, which was similar 
to the median remission of 13  months in another large 
cohort of NPC patients treated with 2-dimensional radi-
otherapy (Yi et  al. 2006). Our current data also showed 
that most distant metastasis occurred within 3 years fol-
lowing initial treatment, with the cumulative metastatic 
rate of 95.6 % (87/91). These data indicate that it may be 
necessary to closely monitor for distant metastasis within 
3  years after treatment. In addition, it is paramount to 
choose an appropriate treatment regime in NPC patients, 
particularly those at high risk of metastases.
In our current study, most patients received CCRT 
based on their clinical staging. The 5-year distant metas-
tasis rate in early stage disease was low, which did not 
associate with IMRT alone or CCRT. To date, there is 
still no consensus that whether stage IIb patients require 
chemotherapy. A previous study reported that IMRT 
combined with CCT did not show any benefit in patients 
with stage IIb NPC (Tham et al. 2010). As recommended 
by National Comprehensive Cancer Network (NCCN) 
clinical practice guidelines of head and neck cancers, 
concurrent cisplatin-based chemoradiotherapy is the 
standard treatment for locally advanced NPC. Our cur-
rent study showed that CCRT treatment of patients with 
stage III and stage IVA–B diseases had 17.5 and 24.2  % 
of the 5-year distant metastasis rate, respectively. For 
locally advanced patients, treatment outcome was not 
satisfactory even with aggressive treatment regimes (Li 
et al. 2015). CCRT alone or CCRT in combination with 
other chemotherapeutic agents in locally advanced NPC 
patients showed no difference in overall survival and 
distant metastasis-free survival, only NACT  +  CCRT 
improved the distant metastasis-free survival compared 
to RT alone (Sun et al. 2013). Theoretically, NACT could 
improve survival by reducing tumor burden and targeting 
micrometastasis. However, additional studies Wu et  al. 
(2014), Qiu et  al. (2016) have not supported these find-
ings. One possible reason for the conflicting results in 
these studies may be differences in patient inclusion cri-
teria. Thus, identifying high-risk metastatic NPC patients 
and applying novel chemotherapeutic regimens including 
molecular targeting agents to treat such patients should 
be the focus of future studies.
In addition, our current data showed that the most 
common sites of cancer metastasis was the lung, followed 
Fig. 2 Kaplan-Meier curve of overall survival for patients with differ-
ent metastatic sites
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by the bone and liver, along with multi-organ metasta-
sis, which was consistent with previous studies (Yi et al. 
2006; Hui et  al. 2004; Cao et  al. 2013). The metastatic 
timing and sites after both IMRT and 2-dimensional 
radiotherapy were similar, indicating that IMRT had 
a limited effect on the control of NPC distant metasta-
sis (Zhang et al. 2015). Previous studies have shown that 
patients with lung metastasis alone had better survival 
(Hui et  al. 2004; Cao et  al. 2011), whereas prognosis of 
patients with liver metastases had a lower survival rate, 
and those with bone metastasis had a lower survival rate, 
although higher than patients with liver metastases (Tian 
et  al. 2013). Similar results were observed in our cur-
rent study. Compared to 2-dimensional radiotherapy, the 
survival benefits of IMRT possibly originated from high 
rates of locoregional control. Thus, novel treatment strat-
egies are needed in order to reduce distant metastasis. 
Furthermore, data from the literature has indicated that 
age, remission duration, and tumor T stage were signifi-
cant predictors for survival of metastatic NPC patients 
(Teo et  al. 1996). Our current study only showed that 
remission duration, treatment modality, and metastatic 
site were independent predictors for overall survival 
of metastatic patients after IMRT and chemotherapy. 
Most patients with cancer distant metastasis were locally 
advanced (86/91 cases) and compared to IMRT alone, 
chemoradiotherapy could improve the prognosis of this 
group of patients.
Conclusion
This study assessed the effects of IMRT and chemother-
apy on NPC patients without initial distant metastasis 
and showed that advanced T, N, and clinical stages plus 
tumor recurrence all contributed to the development of 
distant metastasis. IMRT had no impact on metastatic 
timing and sites of distant metastasis, and remission 
duration, treatment modality, and metastatic sites were 
all independent predictors for overall survival of meta-
static NPC patients after IMRT and chemotherapy. Thus, 
more effective treatment regimes should be explored to 
manage patients with high distant metastasis risk in the 
future.
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